Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger

European Heart Journal

Volumn 27, Issue 19, 2006, Pages 2257-2259

  McMurray, John ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOOP DIURETIC AGENT; NATRIURETIC FACTOR; PERINDOPRIL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

CARDIOVASCULAR RISK; CHRONIC DISEASE; COMORBIDITY; DRUG EFFICACY; EDITORIAL; FOLLOW UP; GERIATRIC PATIENT; HEART EJECTION FRACTION; HEART FAILURE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; PERINDOPRIL; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 33749012266     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl249     Document Type: Editorial

References (11)

1. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43:317-327.
2. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, Aronow WS, Adams KF Jr, Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the Ancillary Digitalis Investigation Group trial. Circulation 2006;114:397-403.
3. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-781.
4. Cleland JG, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M, O'Mahony D, Polonski L, Taylor J. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Fail 1999;1:211-217.
5. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, on behalf of PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-2345. First published on September 8, 2006, doi:10.1093/eurheartj/ehl250.
6. McMurray JJV, Pfeffer MA, Swedberg K, Granger CB, Yusuf S. The CHARM programme. Lancet 2003;362:1678-1679.
7. Pocock S, Wang D, Wilhelmsen L, Hennekens CH. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2005;149:939-943.
8. Pocock SJ. When (not) to stop a clinical trial for benefit. JAMA 2005;294:2228-2230.
9. Carson P, Massie BM, McKelvie R, McMurray J, Komajda M, Zile M, Ptaszynska A, Frangin Gfor the I-PRESERVE Investigators. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 2005;11:576-585.
10. http://topcatstudy.com/index.asp (accessed 27 August 2006).
11. Massie B, Carson P, Komajda M, McKelvie R, McMurray J, Zile M, Frangin G, Ptaszynska A. The baseline characteristics of patients enrolled in the Irbesartan in Heart Failure with Preserved Systolic Function Trial are similar to those in the community but differ from CHARM-Preserved (-Abstract). Heart Failure Society of America 10th Annual Scientific Meeting, Seattle, Washington, September 2006 (http://www.abstracts2view.com/hfsa/).